نتایج جستجو برای: randomized placebo

تعداد نتایج: 282883  

Journal: :Advances in Therapy 2021

In the phase 2 CELEST study, positive efficacy results were obtained with Janus kinase 1 inhibitor upadacitinib for adult patients moderate to severe Crohn’s disease. We present health-related quality of life and work productivity improvement from CELEST. (NCT02365649) was a double-blind study where randomized 1:1:1:1:1:1 in 16-week induction period placebo or 3 mg twice daily (BID), 6 BID, 12 ...

Journal: :European Heart Journal Supplements 2022

Abstract Objectives To rule out a drug-drug interaction (DDI) among cangrelor-treated patients who have been pre-treated with ticagrelor. Background There are no studies specifically designed to DDI when cangrelor is used Methods In this prospective, randomized, double-blind, placebo-controlled, cross-over, pharmacokinetic (PK) and pharmacodynamic (PD) study, coronary artery disease (n = 20) we...

Journal: :Journal of advanced pharmacy education and research 2022

This study investigated the possible therapeutic effects of oral rifampin on patients with acute Central Serous Chorioretinopathy (CSC). clinical trial was a randomized placebo-controlled, double-masked research involving 30 CSC. The were randomly assigned into two groups, one receiving 600 mg once day for month and another being matched placebo group. Best Corrected Visual Acuity (BCVA), subre...

2017
Srdan Verstovsek Ruben A. Mesa Jason Gotlib Vikas Gupta John F. DiPersio John V. Catalano Michael W. N. Deininger Carole B. Miller Richard T. Silver Moshe Talpaz Elliott F. Winton Jimmie H. Harvey Murat O. Arcasoy Elizabeth O. Hexner Roger M. Lyons Ronald Paquette Azra Raza Mark Jones Deanna Kornacki Kang Sun Hagop Kantarjian

BACKGROUND The randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial evaluated the JAK1/JAK2 inhibitor ruxolitinib in patients with intermediate-2/high-risk myelofibrosis. The primary and planned 3-year analyses of COMFORT-I data demonstrated that ruxolitinib-the first myelofibrosis-approved therapy-reduced splenomegaly and prolonged overall survival versus placebo. Here, we pre...

Journal: :Annals of Allergy Asthma & Immunology 2021

BackgroundAtopic dermatitis (AD) is associated with a substantial burden on quality of life (QoL).ObjectiveTo evaluate the effects tralokinumab health-related QoL in patients moderate-to-severe AD using patient-reported outcomes.MethodsThis was phase 2b, randomized, double-blind, placebo-controlled, dose-ranging study adults AD. The received subcutaneous or placebo (1:1:1:1) every 2 weeks for 1...

Journal: :Clinical Pharmacology & Therapeutics 2019

Journal: :Sleep and Biological Rhythms 2022

Abstract The purpose of this study was to investigate the safety and efficacy Rest-ZZZ, a natural sleep supplement, in healthy adults without diagnosed disorder. This randomized, double-blind, placebo-controlled, cross-over consisted three 7-day supplementation periods with either Diphenhydramine (DPH), or Placebo, washout. Twenty-seven participants were randomized one intervention sequences He...

Journal: :Headache 2016
Aruna S Rao Bizu Gelaye Tobias Kurth Paul D Dash Haley Nitchie B Lee Peterlin

OBJECTIVE To compare the efficacy of ketorolac nasal spray (NS) vs. placebo and sumatriptan NS for the acute treatment of migraine. METHODS This was a randomized, double-blind, placebo and active-comparator, crossover study. Adult migraineurs were randomized to ketorolac NS 31.5 mg, sumatriptan NS 20 mg, or placebo to treat three moderate to severe migraine attacks and switched treatments wit...

2016
Muhammad M. Hammami Safa Hammami Reem Al-Swayeh Eman Al-Gaai Faduma Abdi Farah Sophia J. S. De Padua

BACKGROUND Conventional randomized placebo-controlled study design assumes the absence of drug*placebo interaction. We hypothesized the presence of such an interaction and that conventionally estimated drug effect might be biased. The objectives of the study were to determine the drug*placebo interaction effect (main) and compare conventionally estimated and interaction model-estimated drug eff...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید